Therapeutic Area

The World Economic Forum (WEF) recently released a report detailing the ten "world-changing technologies that are poised to rattle the status quo." Let's see for ourselves what these technologies have to offer. Some developments in the bioplastics industry allow lignin, a component of wood, to be broken down into its simpler components using engineered solvents. With this possible, plastics can then be made from it. Lignin is found in wood waste and agricultural byproducts which otherwise doesn't have any other function.

We treat athletes as if they are real-life superheroes that overcome physical challenges to achieve greatness in their respective sports. Today's athletes are physically faster, stronger and more agile than the generation before, but something is wrong. We have not made the same progress in improving athletes' mental skills and health as we have physical skills and health. The focus of any individual or team sport is to maximize player performance. In our sports culture, we are obsessed with team and player statistics using traditional measures in each sport.

With more than 2 billion X-Ray exams done annually, X-Ray is often the hospital's first impression of a patient. Just like first impressions with people, the first image taken helps set the path going forward. "We are getting portable X-Rays all the time for our patients," said Dr. Rachael Callcut, Associate Professor of Surgery at the University of California, San Francisco (UCSF) Medical Center and Director of Data Science for the Center for Digital Health Innovation. "When an X-Ray is taken on a patient, especially a patient who's suffering from an emergent condition or a potentially life-threatening condition, the time that it takes to process, have someone read that and have the image actually come into a queue is a really important time period where minutes and hours matter. For example, a collapsed lung, known as a pneumothorax, is a condition which strikes nearly 74,000 Americans each year[1] and can be deadly if not diagnosed quickly and accurately[2]. A pneumothorax occurs when air leaks into the space between the lung and chest wall. This air pushes on the outside of the lung and makes it collapse. It can be caused by trauma, cigarette smoking, drug abuse, certain lung diseases or be caused by complications from surgery. Today, patients who present with symptoms associated with this condition receive a chest X-Ray, which can take anywhere between two to eight hours to read[3]. Tension pneumothorax or an enlarging pneumothorax can develop as a result of delayed treatment[4], potentially leading to fatal consequences if not treated quickly. This is an example of what may be designated as a "STAT" chest X-Ray, which is supposed to be reserved for potentially life-threatening circumstances. It is a designation on the exam placed at the time of order entry and refers to the ordering provider's determination that the results require immediate interpretation and follow-up. STAT portable chest X-Rays can attribute to more than 60 percent of a radiology center's mobile chest X-ray volume, almost double that of routine exams3. "There's no universally accepted definition of what constitutes a STAT exam," said Dr. Karl Yaeger, a diagnostic radiologist at St. Luke's University Health Network in Bethlehem, Pennsylvania. "Is it STAT because the patient is medically unstable?

Biotechnology, pharmaceutical, and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.

Biotechnology, pharmaceutical, and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.

We all know Elon Musk to be a very ambitious guy. I mean, seriously, the guy has a company which specializes in electric car manufacturing, you've heard of Tesla, right? He also runs an aerospace manufacturing and space transportation services company called SpaceX. I am sure you've heard about it in the news or somewhere else. SolarCity, a solar energy company, now owned by Tesla.

Artificial Intelligence (AI) has provided remarkable capabilities and advances in image understanding, voice recognition, face recognition, pattern recognition, natural language processing, game planning, military applications, financial modeling, language translation, and search engine optimization. In medicine, deep learning is now one of the most powerful and promising tool of AI, which can enhance every stage of patient care --from research, omics data integration, combating antibiotic resistance bacteria, drug design and discovery to diagnosis and selection of appropriate therapy. It is also the key technology behind self-driving car. However, deep learning algorithms of AI have several inbuilt limitations. To utilize the full power of artificial intelligence, we need to know its strength and weakness and the ways to overcome those limitations in near future.

Researchers from MIT and elsewhere have developed a system that detects pain in patients by analyzing brain activity from a wearable neuroimaging device, which could help doctors diagnose and treat pain in unconscious and noncommunicative patients. Researchers from MIT and elsewhere have developed a system that measures a patient's pain level by analyzing brain activity from a portable neuroimaging device. The system could help doctors diagnose and treat pain in unconscious and noncommunicative patients, which could reduce the risk of chronic pain that can occur after surgery. Pain management is a surprisingly challenging, complex balancing act. Overtreating pain, for example, runs the risk of addicting patients to pain medication.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Artificial Intelligence In Behavioral And Mental Health Care market analysis is provided for the international market including development history, competitive landscape analysis, and major regions. Top Key players covered @ AdvancedMD, Cerner, Core Solutions, Credible Behavioral Health, ICANotes, InSync Healthcare Solutions, iSalus Healthcare, Kareo, Meditab Software, Mentegram, Mindlinc, Netsmart, Nextgen Healthcare, NextStep Solutions, Nuesoft Technologies, Qualifacts, Raintree Systems, Sigmund Software, The Echo Group, TheraNest, Valant, Welligent, WRS Health, and many more. The Global Artificial Intelligence In Behavioral And Mental Health Care Industry 2019 Market Research Report is a professional and in-depth study on the current state of the Artificial Intelligence In Behavioral And Mental Health Care market. Development policies and plans are discussed as well as manufacturing processes and cost structures.

Rajarajeshwari Kodhandapani has a dream – to screen one million people for diabetic retinopathy (DR) so they can get timely treatment and not risk going blind. She is one of the four co-founders of Artelus, along with tech veterans Vish Durga, Lalit Pant, and Pradeep Walia, who is also a serial entrepreneur. As a former business analyst, she never thought she would become an entrepreneur (though she did want to become a politician at one time). Now, she is part of Artelus, a company that builds advanced screening tools to allow doctors and hospitals to diagnose a greater number of patients in the same time for a variety of diseases. Today, she wants to reach the people they call the "forgotten billion" – those in rural areas who cannot afford healthcare.